Imbruvica®
(Ibrutinib)  Janssen

Composition:

• New formulation available as tablet containing 140 mg of ibrutinib

Indication(s):

• As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
 

• As a single agent or in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
 

• As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy

• As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy

• In combination with rituximab for the treatment of adult patients with WM

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.